Macleods FDA Monday, August 31, 2026 +0.10 Neutral

FDA Approves SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE ORAL — Macleods Pharmaceuticals Limited

Macleods Pharmaceuticals Limited has received FDA approval for its generic version of Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral, which is expected to generate incremental revenue as market competition intensifies within the oral electrolyte segment. This approval on Aug. 31, 2026, is projected to bolster Macleods' portfolio, providing leverage in the therapeutic area pending generic launch.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed